enfortumab,vedolizumab
takeda,seagen,astellas
['enfortumab', 'mibc', 'ev-104', ' vedo', 'vedo', 'nmibc']
ev-104 ph1 trial. enfortumab vedotin in bcg-unresponsive nmibc. dosing was with 125mg weekly instillation x6 followed by maintenance monthly x9. 3 out of 5 patients had cr. dose escalation is ongoing up to 750mg. i worry with the costs of such treatment. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer